Asia
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
Even before a vaccine for the novel coronavirus has been completely developed, nations across the globe are jockeying for position to lay claim for the potential preventative medicine in something of a healthcare arms race.
Reltecimod is a synthetic peptide antagonist of both superantigen exotoxins and the CD28 T-cell costimulatory receptor.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The U.S. Food and Drug Administration issued a Complete Response Letter to Merck and Eisai over their Lenvima and Keytruda combination for first-line treatment of unresectable hepatocellular carcinoma (HCC).
Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints.
Through the partnership, Takeda will have access to Twist’s “Library of Libraries,” a large phage display library created using precisely defined synthetic DNA sequences to discover unique antibodies to important therapeutic targets including GPCRs.
What if you could get one vaccine that protects you against a wide spectrum of viruses, even viruses we haven’t discovered yet?
Biopharma and life sciences companies provide updates on their pipelines and business plans.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES